Lundbeck CEO Ulf Wiinberg On Partnering For Japan’s CNS Market: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Lundbeck is closely tied with Otsuka for CNS development, giving the company the freedom to explore more R&D programs.
You may also be interested in...
Otsuka And Lundbeck Begin To Reap Rewards Of Partnership
The Japanese company and its Danish partner garnered FDA approval for the long-acting injectable form of the blockbuster antipsychotic Abilify – the first approval of the five compounds the companies are partnered on.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.